Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Forte Biosciences, Inc. (FBRX) EBT (2016 - 2020)

Forte Biosciences (FBRX) has disclosed EBT for 5 consecutive years, with -$4.5 million as the latest value for Q4 2020.

  • On a quarterly basis, EBT rose 57.55% to -$4.5 million in Q4 2020 year-over-year; TTM through Dec 2020 was -$47.0 million, a 208.96% decrease, with the full-year FY2024 number at -$36.6 million, down 12.67% from a year prior.
  • EBT was -$4.5 million for Q4 2020 at Forte Biosciences, up from -$5.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $14.8 million in Q2 2019 to a low of -$34.8 million in Q2 2020.
  • A 5-year average of -$9.2 million and a median of -$9.1 million in 2017 define the central range for EBT.
  • Peak YoY movement for EBT: surged 191.71% in 2019, then tumbled 335.52% in 2020.
  • Forte Biosciences' EBT stood at -$9.0 million in 2016, then decreased by 20.89% to -$10.8 million in 2017, then plummeted by 79.15% to -$19.4 million in 2018, then skyrocketed by 45.49% to -$10.6 million in 2019, then surged by 57.55% to -$4.5 million in 2020.
  • Per Business Quant, the three most recent readings for FBRX's EBT are -$4.5 million (Q4 2020), -$5.0 million (Q3 2020), and -$34.8 million (Q2 2020).